Kazia将ADS ATM发行上限从1亿美元降至8000万美元

----- ea0303789-6k_kazia.htm -----
6-K
1
ea0303789-6k_kazia.htm
REPORT OF FOREIGN PRIVATE ISSUER
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of August 2026
Commission File Number: 000-29962
Kazia Therapeutics Limited
(Exact Name of Registrant as Specified in Its Charter)
Three International Towers Level 24, 300 Barangaroo
Avenue, Sydney NSW 2000
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Filing of Prospectus Supplement
On August 28, 2026, Kazia Therapeutics Limited (the “Company”)
filed a prospectus supplement (the “Prospectus Supplement”) pursuant to Rule 424(b)(5) under the Securities Act of 1933, as
amended, with the U.S. Securities and Exchange Commission. The Prospectus Supplement reduces the maximum aggregate offering price of American
Depositary Shares (“ADSs”) that may be offered, issued and sold under the Sales Agreement, dated March 17, 2026 (the “Sales
Agreement”), by and between the Company and Leerink Partners LLC (“Leerink Partners”), from $100,000,000 to $80,000,000.
The
Prospectus Supplement supplements the Company’s registration statement on Form F-3 (File No.
333-294392
), which was initially filed
with the Securities and Exchange Commission on March 18, 2026.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited
By:
/s/ John Friend
Name:
John Friend
Title:
Chief Executive Officer
Date:
August 28, 2026
2